Actively Recruiting
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
Led by East Coast Institute for Research · Updated on 2025-07-02
70
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
E
East Coast Institute for Research
Lead Sponsor
A
Alcon, a Novartis Company
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.
CONDITIONS
Official Title
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Documented diagnosis of bilateral primary open-angle glaucoma or ocular hypertension
- Completed selective laser trabeculoplasty (SLT) in both eyes within the last 90 days
- Mean diurnal intraocular pressure (IOP) between 16 and 28 mmHg at randomization
- Investigator believes additional IOP reduction could benefit the study eye and that the participant is a candidate for Rhopressa treatment
- Completed required washout period if previously treated with IOP-lowering medications
- If female, participant is either unable to become pregnant, post-menopausal for at least 2 years, or agrees to use effective birth control during the study
You will not qualify if you...
- History of more than one SLT treatment in either eye
- Unable or unwilling to stop current IOP-lowering medications if applicable
- Previous or current treatment with a rho kinase inhibitor
- Prior microinvasive glaucoma surgery (MIGS)
- Advanced glaucoma stage as determined by investigator
- Conditions preventing reliable eye pressure measurement (e.g., corneal abnormalities)
- Previous or active corneal disease affecting study outcomes
- Active or recurrent eye infections or inflammation
- Retinal diseases such as diabetic retinopathy or macular degeneration
- Intraocular injection within 6 months before screening
- Expected use of topical ocular steroids or nonsteroidal anti-inflammatory drugs during the study
- Participation in other drug or device trials or recent investigational drug/device use
- Any condition that might interfere with study results according to investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
East Coast Institute for Research at Florida Eye Specialists
Jacksonville, Florida, United States, 32256
Actively Recruiting
Research Team
R
Rebecca Goldfaden, PharmD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here